Bull of the Day: Alkermes - Bull of the Day

By
A A A

We are impressed by the expanded product portfolio at Alkermes ( ALKS ) following its purchase of Elan's EDT unit. The company continues to expect adjusted earnings per share in the range of $0.88-$1.02 for fiscal 2013. Revenues are still projected in the range of $510-$540 million.

The US approval of type II diabetes drug Bydureon is a major positive for Alkermes as the drug offers significant commercial potential. We are also pleased by the diversified pipeline at Alkermes. The successful development and commercialization of these candidates should boost the company's top line.

We believe that the current price represents an attractive entry point for long-term investors and hence upgrade the stock to Outperform. Our price target of $27.00 is based on 6.8x our fiscal 2013 revenue estimate.

ALKERMES INC (ALKS): Free Stock Analysis Report

To read this article on Zacks.com click here.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: ALKS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com